JAMA by Schuchat, Anne et al.
New Data on Opioid Use and Prescribing in the United States
Anne Schuchat, MD,
Centers for Disease Control and Prevention, Atlanta, Georgia
Debra Houry, MD, MPH, and
Centers for Disease Control and Prevention, Atlanta, Georgia
Gery P. Guy Jr, PhD, MPH
Centers for Disease Control and Prevention, Atlanta, Georgia
The United States is in the midst of an opioid overdose epidemic. Between 1999 and 2010, 
prescription opioid–related overdose deaths increased substantially in parallel with increased 
prescribing of opioids.1 In 2015, opioid-involved drug overdoses accounted for 33 091 
deaths, approximately half involving prescription opioids.2 Additionally, an estimated 2 
million individuals in the United States have opioid use disorder (addiction) associated with 
prescription opioids, accounting for an estimated $78.5 billion in economic costs annually.3 
Proven strategies are available to manage chronic pain effectively without opioids, and 
changing prescribing practices is an important step in addressing the opioid overdose 
epidemic and its adverse effects on US communities.
On July 6, 2017, the US Centers for Disease Control and Prevention reported that between 
2006 and 2015 the amount of opioids prescribed in the United States peaked in 2010 at 782 
morphine milligram equivalents (MME) per capita and then decreased each year through 
2015 to 640 MME per capita. Prescribing rates increased from 72.4 to 81.2 prescriptions per 
100 persons between 2006 and 2010, were constant between 2010 and 2012, and then 
declined to 70.6 per 100 persons from 2012 to 2015, a 13.1% decline.1 Yet the amount of 
opioids prescribed in 2015 remains more than 3 times higher than in 1999, when the amount 
prescribed was 180 MME per capita, and is nearly 4 times higher than in Europe in 2015.
Additional data from the report include that high-dose opioid prescribing, defined as a daily 
dose of 90 MME or higher, was stable between 2006 and 2010, and then declined from 11.4 
per 100 persons in 2010 to 6.7 in 2015.1 Also reported was substantial variation in 2015 at 
the county level from an average of 203 MME per capitain the lowest quartile of counties to 
1319 MME per capita in the highest quartile.
The reduction in opioid prescribing may be related to increasing awareness of the risks 
associated with opioids as well as to state-level policies aimed to reduce inappropriate 
opioid prescribing. During this period (2006-2015), several states implemented policies 
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temporally associated with large decreases in prescribing. For example, Ohio in 2011 and 
Kentucky in 2012 implemented pain clinic regulations and began requiring clinicians to 
review prescription drug monitoring program data.4 From 2010 to 2015, per capita opioid 
prescribing decreased in 85% of the 88 Ohio counties and in 62% of the 114 Kentucky 
counties examined.1 Florida implemented similar policies during this period, and the 
amounts of opioids prescribed decreased in 80% of the 66 Florida counties examined from 
2010 to 2015.1 The policies implemented in these states have been shown to reduce both the 
amount of opioids prescribed and opioid overdose death rates.4 These types of state 
innovations demonstrate that substantial changes are possible.
However, nationally, despite the observed reductions in opioid prescribing, opioid-involved 
overdose death rates continue to increase. These increases are driven largely by the use of 
illicit opioids, such as heroin and illicitly manufactured fentanyl.2 The increase in illicit 
opioids and high levels of prescription opioid use are related. In Rhode Island, 24 of the 69 
people who died from an illicit fentanyl overdose between January 2012 and March 2014 
had filled an opioid prescription within 90 days of death.5 Reducing inappropriate opioid 
prescribing will likely have an important role in addressing illicit opioid use.
There is no evidence that state policies designed to reduce inappropriate opioid prescribing 
are leading to increases in heroin use and deaths from illicit opioid use. In fact, such policies 
have been shown to reduce the amount of opioids prescribed, prescription opioid– involved 
overdose deaths, and all opioid-involved deaths.4 Some evidence also suggests that these 
opioid prescribing policies may reduce heroin overdose deaths.4 By reducing the number of 
people initially exposed to opioids, and the subsequent risk of addiction, these policies may 
actually reduce the number of people initiating illicit use of opioids in the long term.
From 2006 to 2015, the average duration of opioid prescriptions increased by a third, from 
13.3 to 17.7 days. The new data suggest that fewer patients may be initiating prescription 
opioid use, whereas patients already prescribed opioids may be continuing long-term use.1 
Taking opioids for longer periods increases the risk of opioid use disorder, overdose, and 
death. According to a study based on administrative data from 2000 through 2005, patients 
with chronic non-cancer-related pain who took opioids for more than 90 days, even at low 
doses, had a substantially higher odds (odds ratio, 14.92) of developing opioid use disorder 
(absolute rate, 0.72%) compared with those who were not prescribed opioids.6
Understanding these risks may help clinicians evaluate their opioid prescribing patterns and 
potentially reduce long-term opioid use. Before prescribing opioid therapy, clinicians should 
discuss with patients the known risks and realistic benefits of long-term opioid use, regularly 
follow up to determine whether opioids are meeting treatment goals, and examine the 
potential benefits of reducing opioids to a lower dosage, or gradually tapering and 
discontinuing use.
The substantial variation observed in opioid prescribing at the county level, with providers in 
the highest prescribing counties prescribing 6 times more opioids per person than in the 
lowest prescribing counties, suggests inconsistent practice patterns and a lack of consensus 
about appropriate opioid use.1 The CDC Guideline for Prescribing Opioids for Chronic Pain
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—United States, 2016 sets forth evidence-based recommendations about opioid prescribing 
for primary care clinicians treating adults with chronic pain outside of active cancer 
treatment, palliative care, and end-of-life care, and recommends the use of nonopioid 
therapy for treatment of chronic pain.7 The cycle of prescribing opioids begins with 
clinicians. In 2016, the former US surgeon general sent a letter to all licensed physicians and 
issued updated resources on safe prescribing, managing pain, and linking patients to 
addiction treatment as part of the “Turn the Tide” campaign.8 In addition, numerous 
professional societies including the American College of Physicians, the American 
Academy of Family Practice, and the American Medical Association have introduced 
programs to help educate physicians about opioid prescribing.
Beyond changing patterns of prescribing, acomprehensive public health approach is needed 
to address social norms around opioids. A key to reducing the risks associated with long-
term opioid therapy is public awareness regarding the risks of opioid use. CDC has 
developed an upcoming communication campaign about the dangers of prescription opioids 
that includes individuals and families affected by opioid use and misuse and features 
testimonials, images, and powerful messages. Unmasking the devastation of opioid use 
disorder and overdose can help increase population-level understanding of the inherent risks 
of opioids, deter inappropriate use, alert individuals to their own risks of opioid use, and 
improve communication between clinicians and patients.
The epidemic of opioid misuse, overdose, and death is a multifaceted crisis that requires 
partnership across sectors to respond with effective health care and public safety strategies. 
Reducing over-prescribing practices prevents people from becoming addicted in the first 
place, potentially changing the demand for opioids.
Another strategy for reducing harm from opioid overdose is to understand factors related to 
the supply of illicit opioids. At the intersection of law enforcement and public health are 
surveillance activities, data sharing, and rapid response to illicit opioids. As the epidemic 
continues to evolve, deaths linked to illicit opioids such as heroin and fentanyl have 
increased. CDC works with law enforcement to help identify trends in prescribing practices 
and associated risk factors and direct their efforts to emerging illicit threats. In turn, law 
enforcement seizure data help various state and federal agencies target high burden areas to 
focus prevention efforts. The goal is to promote life-saving public health interventions and 
treatments, such as linkage to treatment for substance use disorder and increasing access to 
naloxone to reverse opioid overdose.
Too many individuals in the United States are adversely affected by the opioid crisis, either 
from misuse of prescription opioids or use of illicit opioids. Physicians and other health 
professionals can help prevent many individuals from becoming addicted to opioids or 
overdosing by improving opioid prescribing practices as part of a coordinated public health 
approach.
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